Biotech10 months ago
Novartis Backs Down on Cytokinetics Acquisition
Novartis CEO said that the pharmaceutical company's strategy involves not exceeding acquisitions of more than $5 billion. The agreement with Cytokinetics meant a larger investment, since,...